Protalix Q3 revenue flat at $17.9M; net income down to $2.4M; PRX-115 phase 2 IND effective

Protalix BioTherapeutics, Inc.

2025-Q3 EPS reported -$0.01 vs consensus $0.06 ▼ miss (-118.0%)

Q3 2025 revenue flat at $17.9M; net income $2.4M ($0.03 EPS) vs $3.2M ($0.04) in Q3 2024.
Nine-month 2025 revenue $43.6M (+24% YoY); net loss improved to $1.1M from $3.6M.
PRX-115 IND effective; phase 2 trial for uncontrolled gout planned for late 2025.
Chiesi requested re-examination of CHMP negative opinion on Elfabrio 2 mg/kg E4W; 1 mg/kg E2W still approved.
Cash and equivalents $29.4M at Sep 30, 2025; sufficient for at least 12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.